InflaRx NV
IFRX0.821USD
-0.109-11.68%
Market hours （ET）Quotes delayed by 15 min
19.23MMarket Cap
LossP/E TTM
More Details of InflaRx NV Company
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV Info
Ticker SymbolIFRX
Company nameInflaRx NV
IPO dateNov 08, 2017
CEORiedemann (Niels C)
Number of employees74
Security typeOrdinary Share
Fiscal year-endNov 08
AddressWinzerlaer Str. 2
CityJENA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryGermany
Postal code07745
Phone493641508180
Websitehttps://www.inflarx.de/
Ticker SymbolIFRX
IPO dateNov 08, 2017
CEORiedemann (Niels C)
Company Executives of InflaRx NV
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
467.92K
--
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D
Prof. Niels C. Riedemann, M.D., Ph.D
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mar 5, 2025
Currency: USDUpdated: Mar 5, 2025
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Germany
0.00
0.00%
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Mar 4
Updated: Wed, Mar 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
10.97%
683 Capital Management LLC
4.59%
BofA Global Research (US)
3.42%
Guo (Renfeng M.D.)
2.44%
Eversept Partners, LP
2.43%
Other
76.15%
Shareholders
Shareholders
Proportion
Suvretta Capital Management, LLC
10.97%
683 Capital Management LLC
4.59%
BofA Global Research (US)
3.42%
Guo (Renfeng M.D.)
2.44%
Eversept Partners, LP
2.43%
Other
76.15%
Shareholder Types
Shareholders
Proportion
Hedge Fund
18.80%
Individual Investor
5.98%
Research Firm
5.19%
Investment Advisor
2.11%
Investment Advisor/Hedge Fund
0.90%
Venture Capital
0.18%
Bank and Trust
0.02%
Other
66.83%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
78
18.80M
27.75%
-4.64M
2025Q3
77
16.63M
24.55%
-5.58M
2025Q2
85
22.06M
37.46%
-406.65K
2025Q1
87
22.59M
33.65%
+61.67K
2024Q4
86
18.09M
26.94%
-3.90M
2024Q3
81
17.30M
28.32%
-4.75M
2024Q2
83
17.63M
29.02%
-4.11M
2024Q1
87
18.26M
30.09%
-4.67M
2023Q4
91
21.52M
35.62%
-5.82M
2023Q3
89
23.41M
42.05%
-4.60M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Suvretta Capital Management, LLC
6.48M
9.57%
--
--
Sep 30, 2025
683 Capital Management LLC
2.25M
3.32%
-225.00K
-9.09%
Sep 30, 2025
BofA Global Research (US)
2.48M
3.65%
+2.48M
--
Sep 30, 2025
Guo (Renfeng M.D.)
1.76M
2.6%
--
--
Dec 31, 2024
Eversept Partners, LP
1.73M
2.55%
+90.20K
+5.50%
Sep 30, 2025
Riedemann (Niels C. M.D.)
1.07M
1.58%
--
--
Dec 31, 2024
Morgan Stanley & Co. LLC
626.60K
0.92%
-66.75K
-9.63%
Sep 30, 2025
Mark (Christian Kubler)
960.01K
1.42%
--
--
Dec 31, 2024
Fulpius (Nicolas)
467.92K
0.69%
--
--
Dec 31, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Raymond James SB-1 Equity ETF
0%
Invesco Raymond James SB-1 Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
